Advanced Accelerator Applications – Midgut Carcinoid Tumor

Access Program Information

Advanced Accelerator Applications is currently pursuing marketing approval for
177Lu-DOTA0-Tyr3-Octreotate (Lutathera). Considering that Phase III NETTER-1 clinical trial
recruitment has been completed, this expanded access therapeutic protocol aims to allow
patients suffering from inoperable, somatostatin receptor positive, midgut carcinoid tumors,
progressive under somatostatin analogue therapy to access the investigational product,
177Lu-DOTA0-Tyr3-Octreotate (Lutathera), prior to its commercial availability.